Payment overview · 2025
General Payments
$185.97
10 reported records · 10 companies
Healthcare provider profile · identity verified
Michael John Lillestol, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FARGO, ND · NPI 1669427688
Verified facts
What the public records show
CMS Open Payments records show Michael John Lillestol, M.D. received $185.97 in general payments during 2025 across 10 reported records.
Astellas Pharma US Inc accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.37 | 13.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.15 | 13.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.38 | 12.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.45 | 11.5% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $21.29 | 11.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.31 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.40 | 7.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $14.36 | 7.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.74 | 7.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.52 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.97 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 87 |
| Losartan Potassium | Losartan Potassium | 198 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 53 |
| Ezetimibe | Ezetimibe | 165 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 38 |
| Ozempic | Semaglutide | 106 | 18 |
| Finasteride | Finasteride | 104 | 20 |
| Furosemide | Furosemide | 104 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 22 |
| Prednisone | Prednisone | 87 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 23 |
| Lisinopril | Lisinopril | 85 | 26 |
| Metformin Hcl | Metformin Hcl | 76 | 24 |
| Eliquis | Apixaban | 71 | 18 |
| Omeprazole | Omeprazole | 69 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 16 |
| Lorazepam | Lorazepam | 55 | 12 |
| Tramadol Hcl | Tramadol Hcl | 54 | 12 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 15 |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Carvedilol | Carvedilol | 44 | 11 |
| Gabapentin | Gabapentin | 43 | suppressed |
| Simvastatin | Simvastatin | 41 | 12 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 21 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Azithromycin | Azithromycin | 27 | 27 |
| Bupropion Xl | Bupropion Hcl | 27 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.97 · 10 records | Astellas Pharma US Inc | Ambulatory Monitoring & Diagnostics Undivided, General - Pain Management, Kerendia, NURTEC ODT, OPSUMIT, QULIPTA, REXULTI, REZDIFFRA, UBRELVY, UPTRAVI, VOQUEZNA, Veozah, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error